EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities

Yu Zheng, Yu-Xuan Gao, Mei-Xing Guo, Li-Ting Wang, Xiao-Wen Zheng, Yi-Hao Liao, Ya Li, Jun-Ping Zhu, Jia-Ming Wei

MedComm · 2026-05 · 7 (5)

DOI: 10.1002/mco2.70765 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 13.05.2026. Verfasst von Yu Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine Hunan University of Chinese Medicine Changsha China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 384 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases remain the leading cause of death worldwide. Maladaptive transcriptional programs drive the fibrosis, hypertrophy, and vascular inflammation that characterize these pathologies. Histone posttranslational modifications regulate these programs by remodeling chromatin accessibility and transcriptional output in cardiomyocytes, vascular cells, and immune cells. These modifications include methylation, acetylation, and metabolite‐derived acylations. While the enzymatic machinery of classical histone marks is increasingly well defined, the cell‐type‐specific integration of these regulators into dynamic cardiovascular networks remains incompletely understood. This narrative review summarizes experimental and human studies published up to early 2026. We examine how classical marks such as H3K27me3 and H3K9ac, alongside emerging metabolic sensors like histone lysine lactylation, shape core pathobiological programs, including oxidative stress responses, endothelial dysfunction, and extracellular matrix remodeling, across major cardiovascular syndromes. We further critically evaluate the enzymatic machinery and pharmacological strategies by contrasting broad‐spectrum histone deacetylase inhibition with precision approaches, including bromodomain inhibition and locus‐selective epigenome editing. Finally, we address translational constraints such as drug delivery and off‐target effects. We propose that single‐cell resolution and spatial multiomics will be essential to identify compartment‐specific targets and advance precision cardiovascular epigenetic therapeutics.

Schlagwörter

Stichwörter der Autor:innen

atherosclerosisheart failurehistone posttranslational modificationshypertensionmyocardial infarctionmyocardial ischemia–reperfusion injury

Autor:innen und Institutionen

  • School of Chinese Medicine Hunan University of Chinese Medicine Changsha China.
  • School of Pharmacy Hunan University of Chinese Medicine Changsha China.
  • Institute of TCM Diagnostics Hunan University of Chinese Medicine Changsha China.

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Zheng, Y., Gao, Y. X., Guo, M. X., Wang, L. T., Zheng, X. W., Liao, Y. H., Li, Y., Zhu, J. P., & Wei, J. M. (2026). Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities. MedComm, 7(5). https://doi.org/10.1002/mco2.70765

Vancouver

Zheng Y, Gao YX, Guo MX, Wang LT, Zheng XW, Liao YH, et al. Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities. MedComm. 2026;7(5). doi:10.1002/mco2.70765

BibTeX
@article{Zheng2026,
  author = {Zheng, Yu and Gao, Yu-Xuan and Guo, Mei-Xing and Wang, Li-Ting and Zheng, Xiao-Wen and Liao, Yi-Hao and Li, Ya and Zhu, Jun-Ping and Wei, Jia-Ming},
  title = {Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {5},
  doi = {10.1002/mco2.70765}
}
Kostenlos starten →